ZAK Zürich pp 188-195 | Cite as

Pharmacology of Antagonists of Neuromuscular Blocking Drugs

  • W. C. Bowman
Conference paper
Part of the Anaesthesiologie und Intensivmedizin / Anaesthesiology and Intensive Care Medicine book series (A+I, volume 188)

Abstract

Antagonists of nondepolarizing neuromuscular blocking drugs act by increasing the concentration of the transmitter acetylcholine in the junctional cleft of the neuromuscular junction, so that competition with the blocking drug is shifted in favor of the transmitter, thereby restoring transmission. The concentration of junctional acetylcholine may be increased in two main ways:
  1. 1.

    By inhibiting its breakdown with anticholinesterase drugs or

     
  2. 2.

    By increasing its evoked release from the nerve endings with drugs such as aminopyridines.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Agoston S, Uges DRA, Sia RL (1982) Therapeutic applications of 4-aminopyridine in anaesthesia. In: Lechat P, Thesleff S, Bowman WC (eds) Aminopyridines and similarly acting drugs. Pergamon, OxfordGoogle Scholar
  2. 2.
    Bowden REM, Duchen LW (1976) The anatomy and pathology of the neuromuscular junction. In: Zaimis E (ed) Neuromuscular junction. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 42)Google Scholar
  3. 3.
    Bowman WC (1980) Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg (Cleve) 59:935–943Google Scholar
  4. 4.
    Bowman WE (1980) Pharmacology of neuromuscular function. Wright, BristolGoogle Scholar
  5. 5.
    Bowman WE (1982) Peripheral cholinoceptors. In: Scurr C, Feldman S (eds) Scientific foundations of anaesthesia. Heinemann, LondonGoogle Scholar
  6. 6.
    Bowman WC, Savage AO (1981) Pharmacological actions of aminopyridines and related compounds. Rev Pure Appl Pharmacol Sei 2:317–371Google Scholar
  7. 7.
    Bowman WC, Marshall IG, Gibb AJ (1984) Is there feedback control of transmitter release at the neuromuscular junction? Semin Anesth 3:275–283Google Scholar
  8. 8.
    Brigant JL, Mallart A (1982) Presynaptic currents in mammalian motor endings. J Physiol (Lond) 333:619–636Google Scholar
  9. 9.
    Cronnelly R, Morris RB (1982) Antagonism of neuromuscular block. Br J Anaesth 54:183–194PubMedCrossRefGoogle Scholar
  10. 10.
    Dreyer F (1982) Acetylcholine receptor. Br J Anaesth 54:115–130PubMedCrossRefGoogle Scholar
  11. 11.
    Glover WE (1982) The aminopyridines. Gen Pharmacol 13:259–285PubMedCrossRefGoogle Scholar
  12. 12.
    Hobbiger F (1976) Pharmacology of anticholinesterase drugs. In: Zaimis E (ed) Neuromuscular junction. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 42)Google Scholar
  13. 13.
    Horn AS, Lambert JJ, Marshall IG (1979) A comparison of the facilitatory actions of 4-aminopyridine methiodide and 4-aminopyridine on neuromuscular transmission. Br J Pharmacol 65:53–62PubMedCrossRefGoogle Scholar
  14. 14.
    Neher E, Sakmann B (1976) Single channel currents recorded from membrane of denervated frog muscle fibres. Nature 260:779–802CrossRefGoogle Scholar
  15. 15.
    Peper K, Bradley RJ, Freyer F (1982) The acetylcholine receptor at the neuromuscular junction. Physiol Rev 62:1271–1340PubMedGoogle Scholar
  16. 16.
    Thesleff S (1980) Aminopyridines and synaptic transmission. Neuroscience 6:1413–1419CrossRefGoogle Scholar
  17. 17.
    Webb SN, Bowman WC (1974) The role of pre- and postjunctional cholinoceptors in the action of neostigmine at the neuromuscular junction. Clin Exp Pharmacol Physiol 1:123–134PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • W. C. Bowman

There are no affiliations available

Personalised recommendations